Trial Profile

A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 1951 (Primary) ; Pembrolizumab (Primary)
Indications Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Astellas Pharma Global Development

Most Recent Events

10 Jun 2024 Status changed from completed to discontinued. (Reason the study was stopped: Study was terminated for lack of efficacy.)
02 Aug 2023 Status changed from active, no longer recruiting to completed.
20 Feb 2023 Planned End Date changed from 31 Aug 2023 to 31 Jul 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com